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Translationally controlled tumour protein TCTP is induced early in
human colorectal tumours and contributes to the resistance of HCT116
colon cancer cells to 5-FU and oxaliplatin
Abstract
Background: Translationally controlled tumour protein TCTP is an anti-apoptotic protein frequently
overexpressed in cancers, where high levels are often associated with poor patient outcome. TCTP may be
involved in protecting cancer cells against the cytotoxic action of anti-cancer drugs. Here we study the early
increase of TCTP levels in human colorectal cancer (CRC) and the regulation of TCTP expression in
HCT116 colon cancer cells, in response to treatment with the anti-cancer drugs 5-FU and oxaliplatin.
Methods: Using immunohistochemistry, we assessed TCTP levels in surgical samples from adenomas and
adenocarcinomas of the colon, compared to normal colon tissue. We also studied the regulation of TCTP in
HCT116 colon cancer cells in response to 5-FU and oxaliplatin by western blotting. TCTP mRNA levels were
assessed by RT-qPCR. We used mTOR kinase inhibitors to demonstrate mTOR-dependent translational
regulation of TCTP under these conditions. Employing the Real-Time Cell Analysis (RTCA) System and the
MTS assay, we investigated the effect of TCTP-knockdown on the sensitivity of HCT116 cells to the anti-
cancer drugs 5-FU and oxaliplatin.
Results: 1. TCTP levels are significantly increased in colon adenomas and adenocarcinomas, compared to
normal colon tissue. 2. TCTP protein levels are about 4-fold upregulated in HCT116 colon cancer cells, in
response to 5-FU and oxaliplatin treatment, whereas TCTP mRNA levels are down regulated. 3. mTOR
kinase inhibitors prevented the up-regulation of TCTP protein, indicating that TCTP is translationally
regulated through the mTOR complex 1 signalling pathway under these conditions. 4. Using two cellular assay
systems, we demonstrated that TCTP-knockdown sensitises HCT116 cells to the cytotoxicity caused by 5-FU
and oxaliplatin.
Conclusions: Our results demonstrate that TCTP levels increase significantly in the early stages of CRC
development. In colon cancer cells, expression of this protein is largely upregulated during treatment with the
DNA-damaging anti-cancer drugs 5-FU and oxaliplatin, as part of the cellular stress response. TCTP may thus
contribute to the development of anti-cancer drug resistance. These findings indicate that TCTP might be
suitable as a biomarker and that combinatorial treatment using 5-FU/oxaliplatin, together with mTOR kinase
inhibitors, could be a route to preventing the development of resistance to these drugs.
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Translationally controlled tumour protein
TCTP is induced early in human colorectal
tumours and contributes to the resistance
of HCT116 colon cancer cells to 5-FU and
oxaliplatin
Ulrich-Axel Bommer1,2*, Kara L. Vine1,3, Prianka Puri2,4, Martin Engel1,3, Lisa Belfiore1,3, Karen Fildes1,2,
Marijka Batterham5, Alistair Lochhead1,6,7 and Morteza Aghmesheh1,8
Abstract
Background: Translationally controlled tumour protein TCTP is an anti-apoptotic protein frequently overexpressed
in cancers, where high levels are often associated with poor patient outcome. TCTP may be involved in protecting
cancer cells against the cytotoxic action of anti-cancer drugs. Here we study the early increase of TCTP levels in
human colorectal cancer (CRC) and the regulation of TCTP expression in HCT116 colon cancer cells, in response to
treatment with the anti-cancer drugs 5-FU and oxaliplatin.
Methods: Using immunohistochemistry, we assessed TCTP levels in surgical samples from adenomas and
adenocarcinomas of the colon, compared to normal colon tissue. We also studied the regulation of TCTP in HCT116
colon cancer cells in response to 5-FU and oxaliplatin by western blotting. TCTP mRNA levels were assessed
by RT-qPCR. We used mTOR kinase inhibitors to demonstrate mTOR-dependent translational regulation of
TCTP under these conditions. Employing the Real-Time Cell Analysis (RTCA) System and the MTS assay, we
investigated the effect of TCTP-knockdown on the sensitivity of HCT116 cells to the anti-cancer drugs 5-FU
and oxaliplatin.
Results: 1. TCTP levels are significantly increased in colon adenomas and adenocarcinomas, compared to
normal colon tissue. 2. TCTP protein levels are about 4-fold upregulated in HCT116 colon cancer cells, in
response to 5-FU and oxaliplatin treatment, whereas TCTP mRNA levels are down regulated. 3. mTOR kinase
inhibitors prevented the up-regulation of TCTP protein, indicating that TCTP is translationally regulated through the
mTOR complex 1 signalling pathway under these conditions. 4. Using two cellular assay systems, we demonstrated
that TCTP-knockdown sensitises HCT116 cells to the cytotoxicity caused by 5-FU and oxaliplatin.
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Conclusions: Our results demonstrate that TCTP levels increase significantly in the early stages of CRC development. In
colon cancer cells, expression of this protein is largely upregulated during treatment with the DNA-damaging anti-cancer
drugs 5-FU and oxaliplatin, as part of the cellular stress response. TCTP may thus contribute to the development of
anti-cancer drug resistance. These findings indicate that TCTP might be suitable as a biomarker and that combinatorial
treatment using 5-FU/oxaliplatin, together with mTOR kinase inhibitors, could be a route to preventing the development
of resistance to these drugs.
Keywords: Translationally controlled tumour protein (TCTP), Human colorectal tumours, HCT116 colon cancer cells,
5-fluorouracil (5-FU), Oxaliplatin, PI3-kinase/Akt/mTORC1 signalling pathway, Translational regulation, Chemoresistance
Background
Colorectal cancer (CRC) is a major health problem
worldwide; it is the third most common malignancy di-
agnosed in both men and women, and it affects more
than one million people annually [1–3]. Approximately
50% of people diagnosed with CRC will progress to
metastatic disease, and the average 5-year survival rate is
only 50-60%, resulting in nearly 700,000 deaths world-
wide in 2012 [4]. Early detection of the disease onset is
hampered by the limited availability of suitable bio-
markers. Carcino-embryonic antigen (CEA), still the
most widely accepted prognostic marker in CRC, is
mainly used for disease monitoring after therapy, since
elevated CEA levels are only detected at later stages of
the disease [1, 5]. Therefore, there is a need for develop-
ment of a biomarker that can detect early stage disease
and even early growth, such as adenoma.
Chemotherapy is routinely used for patients with stage
III and IV colon cancer. Standard chemotherapy for ad-
juvant treatment of stage III colon cancer is limited to
oxaliplatin and 5-fluorouracil (5-FU). The same chemo-
therapy drugs are indicated for stage IV disease, in
addition to irinotecan, or for locally advanced or meta-
static disease [6, 7]. There is no other approved chemo-
therapy agent that can be used in colon cancer with
adequate efficacy. Only few biological agents have shown
activity in colon cancer during the last few years [8, 9].
Despite these recent advances, there remains an unmet
need for overcoming resistance to conventional chemo-
therapy [10].
Here we study the regulation of translationally con-
trolled tumour protein (TCTP) both early in the devel-
opment of CRC and in the response of colorectal cancer
cells to treatment with oxaliplatin and 5-FU. TCTP
(gene symbol: TPT1), also referred to as histamine-
releasing factor (HRF) or fortilin, is a highly-conserved,
multifunctional protein, which has been implicated in a
range of cell biological, as well as disease processes, in
particular cancer [11, 12]. One of the best-characterised
functions of TCTP is its anti-apoptotic activity [12–15],
which is underscored by the demonstration that gene
knockout of TCTP in mice is embryonically lethal, due
to excessive apoptosis early in embryogenesis [16, 17].
Moreover, TCTP functions as a cytoprotective protein,
active in cellular responses to a wide range of stresses,
such as oxidative stress [18, 19], heat shock [20], or
Ca++-stress [21]; it is also involved in the cellular DNA
damage repair system [22].
Apart from the cellular stress response, TCTP partici-
pates in various other important biological processes,
such as protein synthesis [23–25], cell division and early
development [11, 12]. TCTP binds to and stabilises mi-
crotubules, inclusive of the mitotic spindle [26]. Detach-
ment of TCTP from the spindle through phosphorylation
by the mitotic protein kinase Plk-1 is essential for the or-
derly progression through both mitotic [27] and meiotic
[28] cell division.
A substantial body of evidence demonstrates that
TCTP is related to cell growth and to the development
of cancer [11, 12, 29, 30]. TCTP is overexpressed in
many cancer cell lines, and its protein levels are posi-
tively related to the growth behaviour of these cells, to
their tumorigenicity [11] and even to their metastatic
potential [31, 32]. Elevated TCTP levels were detected in
a range of human tumours [12], and a high TCTP status
has been associated with a poor outcome in breast [31],
hepatocellular [32], and in ovarian cancers [33], as well
as in gliomas [34]. Work on the experimental ‘tumour
reversion model’ has been instrumental in elucidating
the importance of TCTP early in cancer development
[29, 35, 36]. The anti-apoptotic activity of TCTP has
been described as an underlying mechanism, in particu-
lar its demonstrated antagonism to the tumour suppres-
sor protein p53 [31, 37, 38]. A more recent report has
highlighted the involvement of TCTP in the induction of
the epithelial to mesenchymal transition (EMT), a hall-
mark for the development of cell migration, invasion
and metastasis [39]. Consistent with this, TCTP has
been suggested as an independent prognostic maker for
a poor outcome in breast cancer [31, 40] and in hepato-
cellular cancer [32].
Several reports even propose TCTP as a potential
therapeutic target in breast [31, 40] and prostate cancer
[11, 41], and in neurofibromatosis type 1-associated
Bommer et al. Cell Communication and Signaling  (2017) 15:9 Page 2 of 15
tumours [42]. Successful targeting of TCTP with
antisense-oligonucleotides has been demonstrated in
castration-resistant prostate cancer in mice [41]. Much
earlier, TCTP was described as a target of the antimalar-
ial drug artemisinin in Plasmodium [43]. Dihydro-
artemisinin (DHA) has also anti-cancer activity, and it
targets TCTP in cancer cells [40, 44–46], resulting in
proteasome-mediated degradation and reduction in cel-
lular TCTP levels [40, 45]. In an early study on the
‘tumour reversion model’, several anti-histaminic drugs,
as well as some anti-depressants, were found to be active
in reducing TCTP levels in cancer cells [36]. This led to
the search for further anti-histaminics as TCTP inhibi-
tors with antiproliferative activity [47] and to more
detailed mechanistic studies that underlie the anti-
cancer activity of these antidepressant drugs [29, 31].
Up until recently, relatively little was known about the
role and regulation of TCTP in colorectal cancer. In
former reports, Northern blot analysis was used to dem-
onstrate overexpression of TCTP mRNA in colon car-
cinoma cell lines [48]. In a microarray analysis study,
TCTP mRNA was found to be up-regulated in primary
tumours from colon cancer patients with lymph node
metastases [49]. Two papers reported that TCTP-
knockdown inhibited proliferation, invasion and metastatic
potential of LoVo colon cancer cells [50, 51], indicating
that TCTP is indeed involved in colon cancer progression.
Recently, we demonstrated that growth factor-
dependent expression of TCTP is translationally regu-
lated in both HeLa and HT29 colon cancer cells through
the PI3-K/Akt/mTORC1 signalling pathway [52]. Since
this pathway is frequently upregulated in CRC [53–55],
we hypothesised that overexpression of TCTP in CRC is
driven by this pathway as well. First, we asked whether
the overexpression of TCTP occurs early in the develop-
ment of CRC. We used immunohistochemistry to assess
TCTP protein levels in panels of surgical CRC samples
from adenomas, and adenocarcinomas, compared to sur-
rounding normal colon tissue. We conclude from our
results that, TCTP levels are elevated early in cancer
development. To study the regulation of TCTP in colo-
rectal cancer cells under controlled conditions, we chose
the HCT116 colon cancer cell line. We asked whether
TCTP is regulated in these cells under conditions of
treatment with two drugs commonly used in CRC ther-
apy, 5-FU and oxaliplatin. TCTP protein levels are sig-
nificantly upregulated in these cells by treatment with
either of these two drugs, and this regulation is mediated
through the mTORC1 signalling pathway. Knockdown
of TCTP sensitises HCT116 cells to the treatment
with 5-FU or oxaliplatin, which indicates that TCTP
up-regulation is part of the stress response of colorec-
tal cancer cells to the treatment with these DNA-
damaging anti-cancer drugs. Increased TCTP levels
are therefore likely to contribute to the development
of chemoresistance to these drugs, as it frequently
occurs in CRC.
Methods
Patient samples
To assess TCTP expression levels in paraffin-embedded
surgical samples of colorectal cancer by immunohisto-
chemistry, we performed a database search in the
Pathology records from the Illawarra Cancer Care Centre
of The Wollongong Hospital, and from Southern.IML
Pathology, Wollongong. Based on these records, about 70
patients with a colorectal pathology were selected, with
the aim to obtain an even spread of the following diagno-
ses: adenomas, adenocarcinomas (non-metastatic), and
adenocarcinomas (metastatic; lymph nodes only). Normal
colon tissue was typically identified in the surrounding,
non-malignant tissue of the tumour samples. Ethics
approval for the project was obtained from the Human
Ethics Committee of the University of Wollongong. The
formalin-fixed, paraffin-embedded patient samples were
sourced from the respective Pathology laboratories, freshly
sliced and subjected to immunohistochemistry. Post-
staining, samples were de-identified, numbered and
grouped according to the three pathology types men-
tioned above.
Immunohistochemistry
Immunoperoxidase staining of TCTP expression was
performed on formalin-fixed, paraffin-embedded sec-
tions of the patient samples using the BondmaX auto-
mated processing module (Leica Biosystems). Dewax
and retrieval was performed on board the instrument.
Epitope retrieval was done at low pH for 30 min.
Sections were incubated with the TCTP antibody at
room temperature for 1 h (rabbit polyclonal antibody to
TCTP - AB37506; 1:000). Hydrogen peroxide was
applied after primary antibody to quench endogenous
peroxidase. Detection of the primary antibody was
performed with anti-rabbit poly-HRP-IgG, using DAB as
substrate. Samples were counterstained with HE. The
slides were microscopically inspected and scored
independently by a medical student and two trained
Pathologists. Scoring was performed according to
staining intensity (score 0 – negative, score 1 – weak,
score 2 – strong) and according to numbers of cells
stained (score 0: 0-5% of cells; score 1: 5–75% of cells;
score 2: >75% of cells). The two numerical scores from
intensity and cell percentage were multiplied to give a
final score of 0, 1, 2, or 4. Total score was compared be-
tween groups using a Kruskal-Wallis test with post-hoc
analysis adjusted for multiple comparisons. The analysis
was performed using SPSS V21 (IBM SPSS, IBM
Corporation, Armonk NY, USA).
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Cell lines and culture conditions
The human colorectal carcinoma cell line (HCT116) was
purchased from the American Type Culture Collection
(ATCC, USA) and routinely cultured in RPMI-1640
medium (Invitrogen, USA) containing 10% (v/v) foetal
calf serum (FCS; Thermo, USA). When 80% confluence
was reached, cells were detached by incubation with
5 mM trypsin/EDTA and harvested after centrifugation
in a Heraeus Megafuge 1.0 (Thermo Scientific, USA) at
1200 rpm for 5 min at room temperature. Cells were re-
suspended in media and viable cells counted using a
haemocytometer and trypan blue staining. All cell lines
were confirmed negative for mycoplasma contamination.
Western blot analyses
For preparation of extracts, HCT116 cells were lysed in
NP40 cell lysis buffer (Life Technologies, Burwood, VIC
Australia) with freshly added 1 mM DTT and protease
inhibitor cocktail (Sigma-Aldrich #P8340). Lysates were
centrifuged for 10 min at 15,000 rpm and 4 °C. Superna-
tants were stored at −80 °C and protein concentrations
were determined using the Bradford assay. Equal
amounts of cell extract (typically 15 μg total protein)
were separated by SDS-gel electrophoresis on 12.5%
polyacrylamide gels (Criterion XT precast gels; Bio-Rad,
Gladesville, NSW Australia), and electrophoretically
transferred onto polyvinylidene difluoride (PVDF) mem-
branes. Blots were blocked in 3% (w/v) fat-free milk and
incubated with the indicated primary antibody overnight
at 4 °C. For visualisation, blots were incubated with
HRP-linked secondary antibodies, developed with
Lumi-Glo (Cell Signalling Technology; Genesearch,
Arundel, QLD Australia) and exposed to Kodak X-Omat
film. After scanning (GS-800 scanner; Bio-Rad, Gladesville,
NSW Australia), signals were quantified using the Multi-
Analyst software (Bio-Rad).
Antibodies
Anti-TCTP antibodies AB37506 (polyclonal; for immu-
nohistochemistry), and AB58362 (monoclonal; for west-
ern blotting) were purchased from Abcam (UK) via
Sapphire Bioscience, Waterloo, NSW Australia. Phospho-
ribosomal protein S6 (Ser 240/244; #2215), and sec-
ondary HRP-linked antibodies were from Cell Signalling
Technology, purchased via Genesearch, Arundel, QLD
Australia. Anti-α-and β-tubulin antibodies were from
Amersham Biosciences (UK).
Drugs and inhibitors
Anti-cancer drugs 5-fluorouracil (5-FU) and oxaliplatin
were purchased from Sigma-Aldrich. The drugs were
kept as 10 mM stock solutions in sterile PBS at −20 °C.
The mTOR kinase inhibitors AZD8055 and PP242 were
obtained from Selleck via Life Research, Scoresby,
Victoria Australia. The inhibitors were kept as 10 mM
stock solutions in DMSO at −80 °C.
Quantitation of TCTP mRNA in HCT116 cells by reverse
transcription qPCR
HCT116 cell cultures were treated with 5-FU (20 μM)
or oxaliplatin (12.5 μM) for 48 h (n = 4/group). After
treatment, cultures were processed for RNA extraction
with Tri-reagent (TR 118, Medical Research Centre) ac-
cording to the manufacturer’s instructions. Genomic
DNA was removed using the Ambion Turbo DNA-free
kit, followed by reverse transcription using an M-MLV
reverse transcriptase for 2 h at 37 °C (M1705, Promega).
Quantitative real time PCR was carried out in technical
triplicates on a Light Cycler 480 (Roche) using the SYBR
select master mix (4472918, Life Technologies) accord-
ing to manufacturer’s instructions. Reactions for each
target were optimised for an efficiency >1.8 and specifi-
city was confirmed via melt-curve analysis. The follow-
ing primers (KiCqStart SYBR green, Sigma) were used:
translationally controlled tumour protein (TCTP/TPT1)
(sense, 5’-TACTCTTTCTGGTCTCTGTTC-3’; antisense,
5’-CAAGTTTCACAAAAGAAGCC-3’), and β2-tubulin
(B2T) (sense, 5’-AAGGACTGGTCTTTCTATCTC-3’;
antisense, 5’-GATCCCACTTAACTATCTTGG-3’) at
400 nM in 20 μL reactions with 80 ng cDNA. Treatment
effects on TCTP mRNA expression were assessed using
one-way ANOVA, followed by Tukeys post-hoc analysis,
where applicable. Analyses were performed using SPSS
19.0 (IBM). Statistical significance was accepted at P < 0.05
and data are presented as the mean ± standard error of the
mean (SEM).
TCTP-knockdown
To knock down TCTP expression, HCT116 cells were
transfected with the TPT1-3 siRNA (Ambion) initially,
and more recently with the Silencer SELECT siRNA
(TPT1 Gene; siRNA # s14360) (Ambion; purchased
from Life Technologies Australia) using Lipofectamine™
RNAiMAX as transfection reagent (LifeTechnologies),
according to the reverse transfection protocol for
HCT116 cells provided by the manufacturer (Invitrogen).
The knockdown efficiency was assessed by western blot-
ting from transfection assays in 24-well format; at an
siRNA concentration of 15 nM (48 h), we observed a
knock-down to 6-9% of control TCTP levels. For prolifer-
ation assays and real-time cell analysis assays, the test for-
mat was adjusted to the 96-well plate size. In our
conditions, we noted some off-target effects by the
commercially available control siRNAs; therefore, we
moved to using siRNA for Luciferase, an unrelated gene
not present in mammals, as a control siRNA, or using
GAPDH-siRNA in some experiments.
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Real-time cell analysis
The effect of increasing concentrations of 5-FU or
oxaliplatin on cell proliferation was determined using the
xCELLigence RTCA System (Roche Applied Science) in
specialised 16-well E-16 plates. Transfection mixes contain-
ing Lipofectamine™ RNAiMAX and either TCTP-siRNA,
or Luc-siRNA (in some experiments GAPDH-siRNA) as a
control, were made up in Opti-MEM medium (Life Tech-
nologies). Following the reverse transfection method for
TCTP knock-down experiments, 40 μL of the transfection
mix (or plain Opti-MEM medium for controls) were added
to the wells of the E-16 plates first. Then HCT116 cells
were added at 5000 cells/well in a volume of 140 μL RPMI
medium. The cells were allowed to settle for 30 min at
room temperature before being incubated at 37 °C for 24 h.
Varying concentrations of 5-FU or oxaliplatin (in 20 μL
sterile PBS, pH 7.4) were then added to give a total volume
of 200 μL and the plate then incubated at 37 °C for further
72 h. Comparisons were made to untreated cells, which re-
ceived 20 μL of sterile PBS. The viability and proliferation
of cells was measured as a dimensionless parameter termed
cell index (CI) in real-time. CI is derived from the relative
change in measured electrical impedance, whereby elec-
trical impedance represents the presence and spread of ad-
herent cells. Real-time data was accumulated every 60 min
and graphed using the RTCA-DP Software (version 1.2.1),
supplied with the xCELLigence System.
Cell proliferation assay
The Cell Titre 96® AQueous One Solution Cell
Proliferation Assay (MTS assay, Promega) was used
to evaluate the viability of cells after treatment with the
DNA damaging agents 5-FU or oxaliplatin as described by
Vine et al. [56]. Cells (2–3 × 103 cells/well) were seeded in
96-well plates in a total volume of 180 μL and incubated
at 37 °C, 5% CO2, for 24 h. 5-FU or oxaliplatin (1–
100 μM) were added to the cells (in 20 μL) and incubated
for 72 h. MTS reagent was added and allowed to incubate
for 3 h before the absorbance was measured at 490 nm
using a microplate reader (Spectramax, Molecular
Devices, USA). IC50 values (the dose required to inhibit
the metabolic activity of 50% of the cell population) were
calculated from logarithmic sigmoidal dose response
curves generated using GraphPad Prism v6 software
(GraphPad Inc). Data is presented as a mean ± standard
deviation (SD) from ≥ 2 independent experiments, per-
formed in triplicate.
Results
TCTP is induced early in the development of human
colorectal tumours
In order to detect alterations of TCTP protein levels
early during development of colorectal cancer, we per-
formed immunohistochemistry for human TCTP on
paraffin-embedded surgical samples from about 70 pa-
tients. The patient samples were grouped into three
groups (about 22 patients each), according to the follow-
ing diagnoses: adenomas, adenocarcinomas (non-meta-
static), and adenocarcinomas (metastatic; lymph nodes
only). For comparison, normal colon tissue was identi-
fied during microscopic inspection in the surrounding,
non-malignant tissue of the tumour samples. A panel of
example images from slides of the three tumour groups,
compared to normal tissue, is shown in Fig 1a. Images
C, E and F also provide a direct comparison between
cancerous and adjacent normal tissue.
These images demonstrate that TCTP protein levels
are clearly higher in the tumour samples, compared to
normal colon tissue. To quantify the results, the staining
intensity as well as numbers of cells stained were scored
for each sample as described in the Methods section.
The resulting score figures were compared between
groups and plotted for the three CRC tumour groups,
compared to the normal colon tissue in Fig 1b. Figure 1c
represents the relative score distribution within each tis-
sue group, indicating that higher score numbers are typ-
ically more represented in adenocarcinomas, compared
to adenomas and normal tissue. The results in Fig. 1b
clearly demonstrate a significant increase in TCTP levels
(up to about 3-fold) in the development of colorectal
cancer, during transition from normal tissue to the aden-
oma (P = 0.052) and the adenocarcinoma stage (P = 0.001
for the non-metastatic and P < 0.001 for the metastatic
group). The observation that the investigated tumour
samples display significantly elevated TCTP levels, com-
pared to normal colon tissue, already at the adenoma
stage would indicate the TCTP induction occurs early
during colon cancer development, whereas no changes
were observed during later stages (cf. non-metastatic vs.
metastatic adenocarcinomas, P = 1.000).
We also asked whether there is a correlation of the
TCTP score with other clinic-pathological parameters.
However, we were unable to detect any such correlation
with BMI, age, gender, or measured CEA levels. This
was largely because some of the clinical data were in-
complete and thus the overall sample size was too small
to adequately power the detection of these differences.
TCTP levels are increased in HCT116 colon cancer cells in
response to 5-FU and oxaliplatin
In order to understand how TCTP levels are regulated
in colorectal cancer, we have chosen to study TCTP
regulation in the colon cancer cell line HCT116 under
conditions when cells are subjected to stress induced by
DNA-damaging anti-cancer drugs. TCTP is known to be
a cytoprotective protein that protects e.g. breast cancer
cells from oxidative stress [18] and that is also involved
in the DNA-damage response [22]. We therefore
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anticipated that colon cancer cells would respond to
treatment with such anti-cancer drugs by alterations in
the expression of cytoprotective proteins, such as TCTP,
as part of the cellular stress response. To test this hy-
pothesis for TCTP, we have chosen 5-fluorouracil (5-FU)
and oxaliplatin, two DNA-damaging agents most fre-
quently used in CRC chemotherapy. Treatment of
HCT116 cells with increasing concentrations 5-FU or
oxaliplatin for 24 h or 48 h did indeed result in a signifi-
cant increase in endogenous TCTP protein levels (Fig. 2),
with the most prominent increase occurring after a 48 h
treatment of HCT116 cells with the higher concentrations
of 5-FU. A similar, but less pronounced effect was also
occurring with oxaliplatin.
Induction of TCTP expression in HCT116 colon cancer
cells in response to 5-FU and oxaliplatin is translationally
regulated through the mTORC1 signalling pathway
As for other cytoprotective proteins, TCTP levels can
be translationally regulated as part of a swift re-
sponse, e.g. to cellular stresses. In order to learn
whether the observed upregulation of TCTP in
HCT116 colon cancer cells is due to transcriptional
vs. translational regulation, we assessed the TCTP
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Fig. 1 TCTP protein levels increase significantly in the early stages of human colon cancer development. a Immunohistochemical staining with an
anti-TCTP antibody of paraffin-embedded tumour samples from colon cancer patients with confirmed adenomas (C , D), non-metastatic (E, F) or
metastatic adenocarcinomas (G, H). Areas from surrounding normal colon were used as a control (A, B). Representative examples are shown for each
group at 80 × and 400 × magnification. b Graph showing the average TCTP scoring for each patient group, normalised to TCTP levels in normal colon
tissue (*P = 0.052; **P = 0.001; ***P < 0.001). c Graph representing the score distribution for each patient group (see Methods for scoring)
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mRNA levels in HCT116 cells under these conditions,
using RT-qPCR. The mRNA of β2-tubulin was used
as a reference mRNA. The results plotted in Fig. 3
show that in fact TCTP mRNA levels are not in-
creased, but rather down-regulated through treatment
of HCT cells with 5-FU or oxaliplatin. This effect
appears to be more pronounced in the case of 5-FU
treatment (ca 60% reduction), compared to oxaliplatin
(ca. 40%, P < 0.001 vs. 5-FU). This result shows that
transcriptional regulation is not involved in the
observed increase in TCTP protein levels induced by
5-FU or oxaliplatin (Fig. 2).
We have recently shown that TCTP mRNA transla-
tion is regulated through the PI3-K/Akt/mTORC1
pathway [52]. In order to investigate whether the
mTORC1 pathway might also be involved in the
increase in TCTP protein levels observed here, we
employed two mTOR-kinase inhibitors, AZD8055
and PP242, which inhibited TCTP mRNA translation
more efficiently than the classic mTOR inhibitor
rapamycin [52]. The results shown in Fig. 4 demon-
strate that the increase in TCTP protein levels in-
duced by 5-FU or oxaliplatin is completely inhibited
by the two mTOR kinase inhibitors. In these western
blots, we also probed for the level of phosphorylation
of the ribosomal protein S6 (rpS6) at Ser 240/244,
which serves as a readout of mTORC1 activity, since
mTOR complex 1 activates the p70-S6 kinase, which
in turn phosphorylates rpS6 at these sites [57].
Monitoring rpS6 phosphorylation levels confirms
that, in the presence of AZD8055 or PP242,
mTORC1 is indeed inhibited in our samples. These
results also show that, as for TCTP expression levels,
mTORC1 activity is enhanced with increasing 5-FU
Fig. 2 Treatment of HCT116 colon cancer cells with 5-FU and oxaliplatin results in increased TCTP protein levels. Cells were seeded in 12-well
plates, grown to about 70% confluency and treated with either 5-FU or oxaliplatin at the indicated concentrations for 24 or 48 h. TCTP levels were
assessed by western blotting. The bottom panels show representative western blots for TCTP and α-tubulin as a loading control. TCTP signals
were quantified and normalised for the corresponding α-tubulin signals. In the graphs, normalised TCTP levels are plotted against the drug concentration
for both the 24 h (filled symbols) and the 48 h treatment time (open symbols). Dots represent the average of three experiments ± SD
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Fig. 3 Treatment of HCT116 cells with 5-FU or oxaliplatin results in
decreased TCTP mRNA levels. HCT116 cells were treated with 5-FU
(20 μM) or oxaliplatin (12.5 μM) or culture medium (control) for 48 h
(n = 4). TCTP mRNA levels were assessed by RT-qPCR and normalised
against β2-tubulin mRNA as reference. Values are presented as mean
percentage expression change, compared to untreated control
cells ± SEM (***P < 0.001 vs. control)
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or oxaliplatin concentrations, albeit to a lesser extent
(Fig.4a & b). We conclude from these results that
the elevation of TCTP levels observed in HCT116
colon cancer cells after treatment of with 5-FU or
oxaliplatin is translationally regulated through in-
creased signalling via the mTORC1 pathway.
TCTP partially protects HCT116 colon cancer cells against
the cytotoxic effects of 5-FU and oxaliplatin
To investigate the involvement of TCTP in the protec-
tion of colon cancer cells against DNA damaging anti-
cancer drugs, we performed TCTP knockdown on
HCT116 colon cancer cells and monitored the sensitivity
a
b
Fig. 4 Induction of TCTP expression through 5-FU or oxaliplatin is inhibited by mTOR kinase inhibitors. HCT116 cells were treated for 48 h with 5-FU or
oxaliplatin at the indicated concentrations. Where indicated, AZD 8055 (100 nM) or PP242 (1 μM) were added. TCTP levels were assessed by western
blotting; signals were quantified and normalised against α-tubulin as a loading control. As a readout of mTOR activity, phosphorylation of
the ribosomal protein S6 at Ser 240/244 was assessed using a phospho-specific antibody. a Representative western blots demonstrating
the alteration of the levels of TCTP protein and of phospho-ribosomal protein S6, respectively, in relation to the drug concentration.
b Graphs, showing the alteration of TCTP levels (top graphs) and relative rpS6 phosphorylation levels (bottom graphs) against the drug
concentration, both in the absence (open bars) or in the presence of the mTOR kinase inhibitors AZD8055 (dark grey bars) or PP242
(light grey bars). Bars represent the average of three experiments ± SD
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of these cells to 5-FU and oxaliplatin using the xCELLi-
gence Real-Time Cell Analysis (RTCA) System. This sys-
tem monitors cell growth in real-time by impedance
measurement, and results are recorded as Cell Index
(CI). In Fig. 5a, we show two graphs with representative
growth-curve comparisons for 5-FU- or oxaliplatin-
treatment of cells transfected with either TCTP siRNA
or luciferase siRNA as a control. The right panels dem-
onstrate quantitative comparisons from selected time
points for all drug concentrations and both transfec-
tions. The results show that HCT116 cells transfected
with TCTP-siRNA were more sensitive to 5-FU or oxali-
platin (over a wide concentration range), compared to
HCT116 cells transfected with the non-targeting
Luciferase-siRNA. We conclude from these results that
TCTP is indeed able to partially protect HCT116 cells
against the cytotoxic effects of 5-FU or oxaliplatin,
which confirms our hypothesis that the observed induc-
tion of TCTP synthesis may be part of the cellular
defence in response to the drug treatment.
The RTCA data was then validated using the MTS
quantitative colorimetric cell proliferation assay (Fig. 5b).
Knockdown of TCTP in HCT116 cells resulted in a sig-
nificant decrease in cell viability, 2- and 4-fold after
treatment with 10 μM and 100 μM 5-FU and oxaliplatin,
compared to GAPDH-siRNA transfected HCT116 con-
trol cells. The cytoprotective effect of TCTP was much
reduced at the lowest drug concentration (1 μM)
(Fig. 5b). Overall, the results obtained with the MTS
assay validate our conclusion drawn from the data pre-
sented in Fig. 5a that TCTP protects HCT116 cells
against the cytotoxicity exerted by 5-FU and oxaliplatin.
We also studied the protective effect of TCTP in over-
expression experiments. To this end, we utilised a model
a
b
Fig. 5 TCTP partially protects HCT116 colon cancer cells against toxicity induced by 5-FU or oxaliplatin. a Effect of TCTP knock-down on cellular
sensitivity to 5-FU or oxaliplatin, assessed by the the xCELLigence RTCA System. HCT116 cells were either mock-transfected or transfected with
TCTP siRNA or Luciferase siRNA (as a control) using Lipofectamine™ RNAiMAX transfection reagent for 24 h, and subsequently incubated in the
presence of the indicated concentrations of either 5-FU or oxaliplatin. Cell growth was monitored in real-time using the xCELLigence RTCA System.
Representative growth curves are shown in the left panels for control cells and for treatment with 12.5 μM 5-FU or oxaliplatin, as an example. Relative
cell numbers are expressed as Cell Index (CI). Right panels compare the relative CI-values for Luc-siRNA, and TCTP-siRNA at the time point, when the
control cells reached a CI value of 10 (5-FU treatment) or of 5 (oxaliplatin treatment). b Effect of TCTP knock-down on cellular sensitivity to 5-FU or
oxaliplatin, measured by the MTS endpoint assay for cytotoxicity. TCTP-siRNA or GAPDH-siRNA (as a control) were transfected into HCT116 cells using
Lipofectamine™ RNAiMAX transfection reagent and, after 24 h, incubated in the presence of the indicated concentrations of drugs for another 48 h.
Cell viability was assessed using the MTS endpoint assay and was plotted against the concentration of 5-FU (left graph) and that of oxaliplatin (right
graph). Statistical significance was ascertained using 2WAY ANOVA (****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05)
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cell line that stably overexpresses TCTP, which we had
originally established for a different project [26]. These
are bovine mammary epithelial cells, which harbour ei-
ther a TCTP-overexpressing plasmid or the empty vector
as a control. We used this pair of cell lines, as model
mammalian cells, to demonstrate the protective effect of
TCTP against the cytotoxic action of 5-FU and oxaliplatin
through overexpression, as shown in Additional file 1. In
the RTCA assay, TCTP overexpression displays a clear
protective effect against the 5-FU- and oxaliplatin-induced
cytotoxicity, at least at the higher drug concentrations (left
panels). The results of the MTS assay (right panels) show
the same trend throughout, although the differences be-
tween control cells and TCTP overexpressing cells are
much smaller in this case. The reduced effect observed in
the overexpression experiment, compared to TCTP
knock-down (Fig. 5), can be explained by the fact that the
level of overexpression achieved in these cells is only
about 2-fold, since higher levels of TCTP are not tolerated
by these cells [26]. Overall, our results obtained from both
TCTP-knockdown on HCT116 colon cancer cells and the
TCTP overexpressing model cell line consistently demon-
strate the TCTP is indeed able to protect mammalian
cells, and specifically human colon cancer cells, against
the cytotoxic effects of the DNA-damaging anti-cancer
drugs 5-FU and oxaliplatin.
Discussion
TCTP levels in colon cancer
Enhanced expression of TCTP in colorectal cancer has
been reported previously. However, earlier studies used
colon cancer cell lines, rather than human tumour tissue
[48, 50, 51], or they assessed TCTP mRNA levels via
Northern blotting [48] or via microarray analysis [49],
which does not necessarily reflect alterations in the ex-
pression levels of translationally regulated proteins. Two
studies reporting an increase of TCTP levels in human
colorectal tumours were based on very small sample
sizes of 20 [49], or six patients [58], respectively. Only
the latter study actually compared protein levels (using
proteomics methods), between normal and CRC sam-
ples. In order to consolidate these initial observations
and to better understand the regulation of TCTP expres-
sion in early colon cancer, we undertook this study,
using immunohistochemistry on 70 surgical samples
from human colorectal tumours. Our results demon-
strate that TCTP levels are upregulated in the early stage
of colon cancer development, i.e. in adenomas, and they
reach their maximum levels already at the stage of non-
metastatic adenocarcinoma (Fig. 1). Due to incomplete
availability of clinical data, we were unable to establish a
more precise correlation to tumour staging, or to other
clinical parameters (see results). During the preparation
of this manuscript, a new study was published, describing
similar observations on a group of 134 colon cancer pa-
tients from a Chinese population [59]. These authors also
observed a significant increase in TCTP levels already at
the adenoma stage, and they established an association of
high TCTP levels with high pathological grades, TNM
stage IV and poor patient survival. They also found that
TCTP levels are higher in metastatic tumour samples
compared to primary tumour sites. On the other hand,
colon adenomas displayed TCTP levels comparable to
those of metastases [59]. Taken together, the results of the
Chinese and our study indicate that it would be worth-
while to explore the suitability of TCTP as a biomarker in
the early stages of colon cancer development.
At this point, we are not certain about the mechanism
underlying the early increase in TCTP levels in CRC.
However, we have recently demonstrated that, during
growth-factor dependent induction of HeLa cells, and of
HT29 colon cancer cells, TCTP levels are up-regulated
by signalling through the PI3-K/Akt/mTORC1 pathway
[52]. Since others have shown that the mTOR pathway
is activated early in the development of CRC [60], it is
very likely that activation of this signalling pathway is in-
deed involved in driving the early increase in TCTP pro-
tein levels.
Regulation of TCTP in colon cancer cells in response to
DNA-damaging anti-cancer drugs
Stress-dependent alteration of cellular TCTP levels has
been described for a range of conditions (reviewed in
[11, 12]); for example in cells exposed to heavy metals
[61, 62], to heat shock [20] and to oxidative stress [19, 63].
In particular, TCTP regulation under oxidative stress con-
ditions has been studied in cancer cells, where TCTP was
found to partially protect cells against mild oxidative stress
[14]. The recent finding that TCTP is also involved in the
cellular DNA damage sensing and repair system [22],
prompted us to investigate the regulation of TCTP levels
in colon cancer cells, in response to two anti-cancer drugs
that act as DNA-damaging agents, albeit through different
mechanisms. These two drugs, 5-FU and oxaliplatin, are
the cornerstone drugs used in chemotherapy of CRC.
Treatment of HCT116 colon cancer cells with these drugs
resulted in a dose-dependent increase on TCTP levels,
which was more pronounced after 48 h, compared to 24 h
(Fig. 2). This up-regulation of TCTP is likely to be part of
the cellular stress response to the cytotoxicity caused by
these drugs.
Elevation of TCTP levels in response to oxaliplatin
was reported previously in a proteomics study on three
other colon cancer cell lines (HT29, SW260 and LoVo
cells), where TCTP was found to be one of 21 proteins
upregulated in all three lines [64]. Compared to our re-
sults (Fig. 2), in this study the highest TCTP protein
levels were observed already at the 24 h time point of
Bommer et al. Cell Communication and Signaling  (2017) 15:9 Page 10 of 15
treatment. These findings are consistent with an earlier
paper reporting increased TCTP levels in melanoma cell
lines that are resistant to a range of other anti-cancer
drugs, inclusive of etoposide [65]. In contrast, a later in-
vestigation on gene expression patterns in 5-FU-resistant
vs. normal HCT116 cells failed to detect alterations in
TCTP expression in response to 5-FU treatment [66].
However, this study was based on microarray analysis
comparing relative mRNA expression, which is unlikely to
detect alterations in the expression of genes that are regu-
lated at the translational level. It is also interesting to note
that chemical compounds, which exert their anti-
proliferative effects through different mechanisms, lead to
down-regulation of TCTP expression levels in HCT116
cells [67]. Similarly, antihistaminic [47] or antidepressant
drugs [29] are targeting TCTP and were therefore dis-
cussed as potential options for anti-cancer treatment.
Mechanism of TCTP regulation in response to
DNA-damaging anti-cancer drugs
TCTP may be regulated at the transcriptional or at the
translational level of gene expression, depending on the
type of stress condition applied (reviewed in [11, 12]). In
order to distinguish, which level of regulation applies to
the observed anti-cancer drug dependent increase in
TCTP protein levels (Fig. 2), we assessed the alteration
of TCTP mRNA levels in HCT116 colon cancer cells, in
response to treatment with 5-FU or oxaliplatin. The re-
sults show that TCTP mRNA levels are down- rather
than up-regulated under these conditions (Fig. 3). This
finding indicates that the TCTP mRNA is either tran-
scriptionally downregulated or partly destabilised under
the influence of DNA-damaging anti-cancer drugs; it
also excludes the possibility that transcriptional regulation
is involved in the observed increase in TCTP protein
levels. We did not further investigate the mechanism that
underlies the observed down-regulation of TCTP mRNA.
However, we can exclude a potential artefact due to differ-
ential regulation of different mRNA isoforms, since the
two known species of TCTP mRNAs differ from one an-
other only by an extension at the 3’-end of the longer
mRNA [68]; thus both isoforms are detected by our PCR
primers.
It was surprising to find that, despite of lowered
mRNA levels (Fig. 3), TCTP protein levels are clearly
upregulated in HCT116 colon cancer cells under condi-
tions of treatment with 5-FU and oxaliplatin (Fig. 2).
This could be explained either by a powerful upregula-
tion of mRNA translation, which overrides the effect of
lowered mRNA levels, or by protein stabilisation. TCTP
mRNA belongs to the class of 5’-TOP mRNAs (contain-
ing a 5’-terminal oligopyrimidine tract, 5’-TOP) [69],
whose translational activity is largely controlled through
the mTOR pathway [70]. Consistent with this, during
growth-factor dependent up-regulation of TCTP in can-
cer cells, TCTP mRNA translation is regulated through
the PI3-K/Akt/mTORC1 pathway [52]. Therefore, we
asked whether the observed increase in TCTP protein
levels in response to 5-FU or oxaliplatin treatment
(Fig. 2) is also regulated through mTOR. Using two
mTOR-kinase inhibitors, we showed that these nearly
completely inhibited this increase in TCTP levels (Fig. 4).
This result indicates that TCTP protein expression is in-
deed regulated through the mTORC1 pathway, and it
provides additional evidence for translational regulation
of TCTP expression under these conditions.
Our observation is contrasting to the well documented
believe that cellular stresses, such as hypoxia or geno-
toxic stress (DNA damage), typically result in an inhib-
ition of mTORC1 activity [71]. Whilst inactivation of
mTORC1, and consequently shut down of protein syn-
thesis under cell stress conditions, is generally a sensible
biological response, there are also instances, which
should allow for exceptions. One of the early papers es-
tablishing the link between DNA damage and mTOR
regulation observed that initially mTOR inhibition is still
reversible; it becomes irreversible only after entry of cells
into apoptosis [72]. Also, a distinction has to be made
between high and low levels of stress. For example,
PTEN, the negative regulator of the PI3-K/Akt/
mTORC1 pathway, was found to be suppressed in the
colon cancer cell lines HT29 and LoVo at low concen-
trations of 5-FU and oxaliplatin, allowing for activation
of the pathway [73]. This is reminiscent of the regulation
reported for TCTP under oxidative stress in breast can-
cer cells, where mild stress resulted in increased TCTP
levels, whereas harsh stress conditions led to reduced
TCTP levels [18].
TCTP is in the same league with other, well-known
anti-apoptotic proteins, in that these proteins all have a
cytoprotective function, they are involved in cancer and
they are translationally regulated through the mTORC1
pathway. Examples are the proteins Bcl-2 and Bcl-XL
[74], Mcl-1 [75, 76], and survivin, which was shown to
be important for promoting motility and metastasis in
CRC via translational control mechanisms [77]. Both,
Bcl-XL and Mcl-1 have been identified as interaction
partners of TCTP (reviewed in [11, 12, 14]), and they
have been shown to contribute to enhanced resistance of
colorectal cancer cells against 5-FU and oxaliplatin [78].
Recently, a mechanism has been described, by which
mTORC1 may be regulated by Bcl-2 and Bcl-XL, i.e. via
competition for binding to the mTORC1 inhibiting
protein FKBP38 [79]. This is interesting for two reasons:
1. TCTP itself has been implicated in the regulation of
mTORC1 in Drosophila, through interaction with Rheb
[80], although other studies found different results in
mammalian cells [81, 82]. 2. Enhanced Bcl-XL could
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locally activate mTORC1 [79], and this could explain the
observed mTOR-dependent up-regulation of TCTP in
the presence of 5-FU. Certainly, there are mechanisms
in place to maintain (or even enhance) the synthesis of
cytoprotective proteins under stress conditions, when
general protein synthesis is shut down [71], however this
needs to be shown for each protein individually.
Previous studies aimed at targeting TCTP in cancer
cells have identified three groups of established drugs
that are able to reduce intracellular TCTP levels, i.e. the
antimalarial drug artemisinin [40, 45, 46], anti-histaminics
[36, 47] and certain anti-depressants [29, 36]. Of the latter,
sertraline, a selective serotonin reuptake inhibitor (SSRI),
is of particular interest in the context of colorectal cancer.
The potential anti-cancer activity of sertraline was demon-
strated in human colon cancer cell lines and in CRC xeno-
grafts in mice [83], and two epidemiologic studies, in
Canada [84] and the US [85], showed that the use of SSRIs
reduces the risk of colorectal cancer. Two potential mech-
anisms have been proposed for sertraline’s anti-cancer
activity: 1. Sertraline interferes with the reciprocal repres-
sive feedback loop between TCTP and the tumour sup-
pressor P53 [31] by preventing the binding of TCTP to
MDM2 and consequently the destabilisation of P53
caused by TCTP [29]. 2. Sertraline has been shown to in-
hibit translation initiation at the level of eIF4F complex
formation, by an increase in eIF2α phosphorylation and
by directly interfering with the mTORC1 pathway [86].
We have established that TCTP mRNA translation is sub-
ject to positive regulation through eIF4E [87] and the
mTORC1 pathway [52], as well as to negative regulation
by PKR and through eIF2α phosphorylation [21, 88]. It is
therefore very likely that sertraline reduces TCTP levels
also by inhibiting translation initiation. As mentioned be-
fore, other anti-apoptotic proteins are also translationally
regulated through the mTOR pathway and therefore may
be inhibited by sertraline; this has already been shown for
Bcl-2 in CRC cells [83]. All these studies indicate that it
would be worthwhile to further explore – and exploit -
the anti-cancer activity of sertraline, alone or in combin-
ation with 5-FU or oxaliplatin in CRC.
Cytoprotective role of TCTP in cancer
In order to demonstrate the functional importance of in-
creased TCTP expression in response to 5-FU and oxali-
platin, we also asked whether increased TCTP levels are
able to protect HCT116 cells against the cytotoxic ef-
fects of these drugs. Using cytotoxicity assays, we tested
the effect of TCTP-knockdown on the sensitivity of
these cells to 5-FU and oxaliplatin, and showed that it is
indeed increased after TCTP-knockdown (Fig. 5). Consist-
ent with this, TCTP overexpressing partially protected
cells against 5-FU and oxaliplatin (Additional file 1). The
cytoprotective effect of TCTP in cancer cells has been
demonstrated for various cell stress conditions (reviewed
in [11, 12, 14]). The involvement of TCTP (also named
fortilin) in the protection of cancer cells against anti-
cancer drugs has been reported in other settings as well,
e.g. for etoposide in HeLa cells and in U2OS cells [89],
and for 5-FU in U2OS cells [90].
It is therefore very likely that TCTP is involved in the
development of anti-cancer drug resistance, a wide-
spread problem in cancer chemotherapy. Indeed, an
early study on chemoresistant melanoma cells showed
that, among other proteins, TCTP is overexpressed in
these cells [65]. A more recent study demonstrated the
overexpression of TCTP (also called HRF) in non-
Hodgkin lymphomas, and it established a role for this
protein in cell adhesion and drug resistance [91]. On the
other hand, a recent detailed investigation on gene sig-
natures for drug resistance in HCT116 cells has failed to
detect TCTP (TPT1) as a gene potentially regulated
under these conditions [92]. However, this study was
based entirely on microarray data and is therefore un-
likely to detect translationally controlled genes.
Apart from being involved in chemoresistance of can-
cer cells, TCTP has been shown to play a significant role
in the later stages of tumour development, which en-
compass the cellular properties of epithelial to mesen-
chymal transition (EMT), migration, invasion and
metastasis. This has been demonstrated for a range of
cancer cells [11, 39, 41], and specifically for colon cancer
[51, 59]. Our observation that average TCTP levels
increase early in CRC, with less elevation from the
adenocarcinoma to the metastatic stage (Fig. 1), is
consistent with the report from others [59], showing
that TCTP levels of metastatic samples are not much
higher than those of colon adenomas. One has to
keep in mind that there is a considerable variability
in TCTP levels between individual patients, within
each, the non-metastatic and the metastatic group of
adenocarcinomas. A high TCTP status has been asso-
ciated with a poor patient outcome for CRC [59] and
for a range of other cancer types [31–34]. All these
findings suggest that TCTP is a potential biomarker
and a target for anti-tumour therapy, which has been
proposed for various types of cancers [11, 40–42].
Conclusions
Our results on the expression of TCTP early in develop-
ment in CRC support the view that TCTP could be
potentially explored as a biomarker in colon cancer, to as-
sist in the detection of early tumour growth and to iden-
tify patients with a high TCTP status. Indeed another
study has provided initial results on increased serum
TCTP levels in colon cancer patients [59]. The main con-
clusion from our results on colon cancer cells is that
TCTP is very likely involved in the development of anti-
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drug resistance against 5-FU and oxaliplatin, the most
widely used chemotherapeutic agents in CRC. It is there-
fore worthwhile to explore its suitability as a biomarker
for chemoresistance and as an anti-cancer target in che-
moresistant tumours. Our finding that up-regulation of
TCTP in response to 5-FU and oxaliplatin is regulated
through the mTORC1 pathway would suggest that com-
binatorial treatment with 5-FU/oxaliplatin, together with
mTOR inhibitors, could be a suitable approach.
Additional file
Additional file 1: TCTP overexpression partially protects mammalian
cells against the cytotoxic effects of 5-FU and oxaliplatin. We utilised a
previously established model cell line that stably overexpresses TCTP [26].
These are bovine mammary epithelial cells, where one line harbours a
TCTP-overexpressing plasmid (white bars), and the control cell line the
empty vector (black bars). The cells were cultured in DMEM supplemented
with 10% FCS, 50 mg/ml hygromycin B and 5 mg/ml insulin. Cells
were subjected to treatment with the indicated concentrations of
5-FU or oxaliplatin. Cell growth was monitored in real-time using the
xCELLigence RTCA System (left graphs), or using the MTS endpoint
assay for cytotoxicity (right graphs). Cell numbers were plotted as
relative cell index (CI) after 72 h of drug treatment (left graphs), or
as relative cell viability for the MTS assay after 48 h of treatment
(right graphs), against the indicated concentrations of 5-FU (top
graphs) or oxaliplatin (bottom graphs). (PPTX 283 kb)
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